Sugen Incorporated

University of California

Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Bio-signal Corporation Ltd.

Other

Janis Haimichael

Axel Ullrich

Istvan Szekely

Klaus Peter Hirth

Reiner Lammers

Aviv Gazit

Laura Kay Shawver

Alex Levitzki

Elaina Mann

Tamas Bajor

Peng Cho Tang

Donna Pruess Schwartz

Gyorgi Keri

Dennis J Slamon

Fairooz F Kabbinavar

Laura K Shawyer

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG.,), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Treatment of platelet derived growth factor related disorders such as cancers

The present invention concerns compounds which can inhibit platelet derived growth factor receptor (PDGF-R) activity, preferably such compounds also inhibit the activity other members of the PDGF-R super family and are selective for members of the PDGF-R super family. The PDGF-R super family includes PDGF-R and PDGF-R related kinases Flt, and KDR. The featured compounds are active on cell cultures to reduce the activity of the PDGF-R and preferably one or more PDGF-R related kinases. An example of a featured compound, A10 (see FIG. 1a), and its ability to inhibit growth of tumor cells in vivo is described below. Using the present application as guide other compounds able to inhibit PDGF-R and preferably Flt and/or KDR can be obtained. Such compounds are preferably used to treat patients suffering from cell proliferative disorders characterized by inappropriate PDGF-R activity.

Treatment of platelet derived growth factor related disorders such as

Method for treating a patient inflicted with a cell proliferation disorder, such as a cancer, characterized by inappropriate PDGF-R activity. The method involves the step of administering to the patient a therapeutically effective amount of a composition described in application.

Growing community of inventors

Budapest, Hungary

Janis Haimichael